BPC-157
Also known as: Body Protection Compound-157, Bepecin, PL 14736, PL-10
Grey-Market Compound. This compound is not approved by the FDA or any major regulatory authority. No established regimen exists. Products available outside of regulated channels lack standardized manufacturing, quality control, and potency verification. Consult a qualified clinician. Research-only risks apply.
Overview
Clinical Summary
BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. It has been studied extensively in preclinical models for tissue repair, angiogenesis, and cytoprotection. Despite a large body of animal research, human clinical trial data remain extremely limited. BPC-157 is widely used in the grey market for injury recovery, though its efficacy in humans has not been established through rigorous clinical trials.
Plain Language Summary
BPC-157 is a lab-made peptide based on a protein found naturally in stomach acid. In animal studies, it has shown remarkable healing properties for muscles, tendons, ligaments, the gut lining, and other tissues. However, there are very few human studies, so we do not know for certain whether these effects translate to people. It is popular among athletes and biohackers but is not an approved medication anywhere.
Mechanism of Action
BPC-157 appears to exert tissue-protective and repair-promoting effects through multiple proposed mechanisms: upregulation of growth factor expression (VEGF, EGF, and others) promoting angiogenesis and tissue granulation; modulation of the nitric oxide system; interaction with the dopaminergic, serotonergic, and GABAergic systems; cytoprotective effects on the GI mucosa; and anti-inflammatory activity. The peptide has been shown to promote tendon, ligament, muscle, and bone healing in rodent models. The precise molecular targets and binding partners remain incompletely characterized.
Evidence Summary
The evidence base for BPC-157 consists almost entirely of preclinical (rodent) studies, of which there are over 100 published. These demonstrate accelerated healing of tendons, ligaments, muscles, skin, and GI mucosa. A few small human studies have explored oral BPC-157 for inflammatory bowel disease (Phase 2), but results have not been fully published. There are no completed, peer-reviewed RCTs in humans for musculoskeletal indications. The quality of available evidence is limited by the reliance on animal models and the absence of pharmacokinetic data in humans.
Safety Profile
No serious adverse events have been reported in the limited human exposure data. Animal studies have not identified significant toxicity. However, the absence of systematic safety assessment in humans means that the safety profile is not established. Theoretical concerns include effects on angiogenesis (could theoretically promote tumor vascularization, though no evidence supports this), unknown long-term effects, and quality/purity concerns with grey-market products.
Contraindications
- Known hypersensitivity
- Active malignancy (theoretical concern due to angiogenic properties)
- Pregnancy and breastfeeding (no safety data)
Adverse Events
- Injection site irritation (anecdotal reports)
- Nausea (oral administration, anecdotal)
- Dizziness (rare, anecdotal)
- Safety profile not systematically characterized in humans
Interactions
- No formal interaction studies exist
- Theoretical interaction with anticoagulants (angiogenic properties)
- Unknown interactions with other peptides
Active Safety Signals
In 2023, the FDA added BPC-157 to the list of substances that cannot be used in compounding under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This means licensed compounding pharmacies in the US cannot legally prepare BPC-157 for patients. Products available in the grey market lack pharmaceutical quality controls.
Regulatory Notes
BPC-157 is not approved by the FDA, EMA, or any major regulatory authority for any indication. In the United States, the FDA has issued warning letters to companies selling BPC-157 for human use. It is classified as a research chemical. The peptide is widely available in the grey market, but products lack standardized manufacturing, quality control, and potency verification. In 2023, the FDA added BPC-157 to the list of substances that cannot be used in compounding.
Monitoring Considerations
No established monitoring protocols exist. General considerations include baseline and follow-up assessment of the target condition. Given the angiogenic mechanism, awareness of any unusual tissue growth or vascular changes may be prudent. Quality of product cannot be verified without third-party testing.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
As a peptide, BPC-157 is susceptible to degradation. Grey-market products vary widely in actual peptide content, purity, and stability. No standardized stability data are available for non-pharmaceutical preparations.
References
- 1review
Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Sikiric P, Seiwerth S, Rucman R, et al. (2014). Current Pharmaceutical Design
Key findings: Comprehensive review of BPC-157 preclinical data including GI cytoprotection, wound healing, and tissue repair across multiple organ systems.
Limitations: Review of predominantly preclinical data by the primary research group.
- 2preclinical
Pentadecapeptide BPC 157 and Its Effects on a NSAID Toxicity Model
Seiwerth S, Sikiric P, et al. (2020). European Journal of Pharmacology
Key findings: Demonstrated cytoprotective effects against NSAID-induced GI damage in rodent models.
Limitations: Animal study; not directly translatable to human use.
- 3review
BPC 157: A Review of Its Preclinical and Clinical Pharmacology
Gwyer D, Wragg NM, Wilson SL. (2019). International Journal of Molecular Sciences
Key findings: Independent review highlighting robust preclinical evidence but noting the near-complete absence of human clinical data.
Limitations: Confirms the gap between preclinical promise and clinical evidence.
View source
Last reviewed: 2024-12-10 | Version: 1 | Status: Published